Healthpeak Properties, Inc. (DOC)

Theseus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	164.92	243.14	306.01	500.45	505.54	413.56
Depreciation & Amortization	1,028	996.31	725.89	688.93	665.69	544.23
Other Amortization	32.86	28.97	11.92	10.88	9.22	10.16
Gain (Loss) on Sale of Assets	-55.03	-178.7	-86.46	-33.12	-605.31	-592.16
Gain (Loss) on Sale of Investments	0.43	-77.55	-0.23	-311.44	-1.04	-159.97
Asset Writedown	4.34	15.31	-7.69	7	55.9	244.25
Stock-Based Compensation	13.73	15.54	14.48	26.46	18.2	17.37
Income (Loss) on Equity Investments	18.3	13.52	-9.29	-1.11	-6.26	80.08
Change in Accounts Receivable	-29.31	-40.86	-21.57	-17.43	18.63	15.28
Change in Accounts Payable	114.35	85.64	104.51	136.29	7.77	93.5
Other Operating Activities	-55.66	-38.5	-83.41	-106.66	126.92	-51.06
Net Cash from Discontinued Operations	-	-	-	-	-	143.19
Operating Cash Flow	1,245	1,070	956.24	900.26	795.25	758.43
Operating Cash Flow Growth	30.57%	11.95%	6.22%	13.21%	4.85%	-10.36%
Acquisition of Real Estate Assets	-848.06	-720.07	-860.65	-1,148	-2,205	-2,056
Sale of Real Estate Assets	284.16	648.55	141.65	47.89	2,399	1,304
Net Sale / Acq. of Real Estate Assets	-563.89	-71.52	-719	-1,100	194.06	-751.96
Cash Acquisition	-	-179.22	-	-	-	-394.18
Investment in Marketable & Equity Securities	-55.39	86.97	-67.75	117.36	12.38	-20.56
Other Investing Activities	6.3	8.71	24.98	1.45	-	1.8
Investing Cash Flow	-644.52	-113.8	-576.75	-876.34	531.03	-1,008
Long-Term Debt Issued	-	4,491	11,088	16,382	17,910	5,337
Total Debt Issued	7,823	4,491	11,088	16,382	17,910	5,337
Long-Term Debt Repaid	-	-4,338	-10,710	-16,058	-18,211	-5,274
Total Debt Repaid	-7,409	-4,338	-10,710	-16,058	-18,211	-5,274
Net Debt Issued (Repaid)	414.1	153.22	378.08	324.58	-301.01	63
Issuance of Common Stock	0.31	0.32	0.28	308.1	5.04	1,069
Repurchase of Common Stock	-117.5	-190.69	-6.52	-67.84	-12.84	-10.53
Common Dividends Paid	-845	-794.78	-657.02	-648.05	-650.08	-787.07
Other Financing Activities	-48.06	-109.48	-52.12	-33.33	-329.62	-87.82
Foreign Exchange Rate Adjustments	-	-	-	-	-	-0.15
Net Cash Flow	3.98	15.28	42.19	-92.61	37.76	-2.97
Cash Interest Paid	257.54	249.47	188.21	162.12	173.04	209.84
Cash Income Tax Paid	5.12	7.86	1.92	-1.9	4.52	-0.79
Levered Free Cash Flow	651.28	798.48	953.92	958.39	2,722	1,585
Unlevered Free Cash Flow	801.15	944.77	1,067	1,056	2,812	1,711
Change in Net Working Capital	562.24	371.18	-60.5	-93.84	-1,914	-1,025

Updated Jul 24, 2025. Source: S&P Global Market Intelligence. Real Estate template. Financial Sources.

SEC Filings: 10-K · 10-Q